Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
GermanyIPO:
05 November 2021Website:
http://mainzbiomed.comNext earnings report:
15 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 23:47:57 GMTDividend
Analysts recommendations
Institutional Ownership
MYNZ Latest News
Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Sept.
BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed's mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm BERKELEY, Calif. and MAINZ, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company's mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer prevention BERKELEY, Calif. and MAINZ, Germany, May 20, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
What type of business is Mainz Biomed BV?
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
What sector is Mainz Biomed BV in?
Mainz Biomed BV is in the Healthcare sector
What industry is Mainz Biomed BV in?
Mainz Biomed BV is in the Diagnostics & Research industry
What country is Mainz Biomed BV from?
Mainz Biomed BV is headquartered in Germany
When did Mainz Biomed BV go public?
Mainz Biomed BV initial public offering (IPO) was on 05 November 2021
What is Mainz Biomed BV website?
https://mainzbiomed.com
Is Mainz Biomed BV in the S&P 500?
No, Mainz Biomed BV is not included in the S&P 500 index
Is Mainz Biomed BV in the NASDAQ 100?
No, Mainz Biomed BV is not included in the NASDAQ 100 index
Is Mainz Biomed BV in the Dow Jones?
No, Mainz Biomed BV is not included in the Dow Jones index
When was Mainz Biomed BV the previous earnings report?
No data
When does Mainz Biomed BV earnings report?
The next expected earnings date for Mainz Biomed BV is 15 November 2024